GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (BSP:R1VT34) » Definitions » Cyclically Adjusted PS Ratio

Revvity (BSP:R1VT34) Cyclically Adjusted PS Ratio : 3.67 (As of May. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Revvity Cyclically Adjusted PS Ratio?

As of today (2024-05-24), Revvity's current share price is R$18.52. Revvity's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was R$5.04. Revvity's Cyclically Adjusted PS Ratio for today is 3.67.

The historical rank and industry rank for Revvity's Cyclically Adjusted PS Ratio or its related term are showing as below:

BSP:R1VT34' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.97   Med: 3.9   Max: 7.91
Current: 3.94

During the past years, Revvity's highest Cyclically Adjusted PS Ratio was 7.91. The lowest was 1.97. And the median was 3.90.

BSP:R1VT34's Cyclically Adjusted PS Ratio is ranked worse than
67.91% of 134 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.37 vs BSP:R1VT34: 3.94

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Revvity's adjusted revenue per share data for the three months ended in Mar. 2024 was R$0.936. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is R$5.04 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Revvity Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Revvity's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Cyclically Adjusted PS Ratio Chart

Revvity Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.61 6.52 7.91 5.13 3.91

Revvity Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.80 4.24 3.93 3.91 3.70

Competitive Comparison of Revvity's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Revvity's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revvity's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Revvity's Cyclically Adjusted PS Ratio falls into.



Revvity Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Revvity's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=18.52/5.04
=3.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revvity's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Revvity's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.936/131.7762*131.7762
=0.936

Current CPI (Mar. 2024) = 131.7762.

Revvity Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.390 100.560 0.511
201409 0.398 100.428 0.522
201412 0.367 99.070 0.488
201503 0.521 99.621 0.689
201506 0.551 100.684 0.721
201509 0.692 100.392 0.908
201512 0.555 99.792 0.733
201603 0.592 100.470 0.776
201606 0.597 101.688 0.774
201609 0.543 101.861 0.702
201612 0.616 101.863 0.797
201703 0.521 102.862 0.667
201706 0.581 103.349 0.741
201709 0.559 104.136 0.707
201712 0.677 104.011 0.858
201803 0.677 105.290 0.847
201806 0.850 106.317 1.054
201809 0.885 106.507 1.095
201812 0.940 105.998 1.169
201903 0.800 107.251 0.983
201906 0.892 108.070 1.088
201909 0.932 108.329 1.134
201912 1.058 108.420 1.286
202003 1.020 108.902 1.234
202006 1.345 108.767 1.630
202009 1.656 109.815 1.987
202012 0.384 109.897 0.460
202103 2.339 111.754 2.758
202106 1.963 114.631 2.257
202109 1.412 115.734 1.608
202112 1.638 117.630 1.835
202203 1.352 121.301 1.469
202206 1.276 125.017 1.345
202209 1.053 125.227 1.108
202212 1.100 125.222 1.158
202303 0.993 127.348 1.028
202306 0.980 128.729 1.003
202309 0.953 129.860 0.967
202312 0.987 129.419 1.005
202403 0.936 131.776 0.936

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Revvity  (BSP:R1VT34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Revvity Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Revvity's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Revvity (BSP:R1VT34) Business Description

Traded in Other Exchanges
Address
940 Winter Street, Waltham, MA, USA, 02451
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Revvity (BSP:R1VT34) Headlines

No Headlines